What Decides Which Biologic You Get

Where biologics sit in psoriasis care

Biologics are not usually the first thing anyone tries for psoriasis. They enter the picture for moderate-to-severe disease, or when psoriasis has a large impact on life and gentler options have not been enough. The usual sequence — the psoriasis treatment ladder — starts with topical treatments for limited disease, often adds light-based treatment such as narrowband uvb, and moves to systemic medicines, including biologics, when the disease is extensive or stubborn 1Ref 1American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with phototherapy.That phototherapy such as narrowband UVB is a recognized tier of psoriasis treatment, sitting between topical therapy and systemic biologics in the usual sequence of care..

It helps to know what a biologic is: a targeted, usually injected medicine that blocks a specific messenger in the immune system, rather than broadly suppressing it the way some older systemic drugs do. That precision is part of what makes the class both effective and, in general, well tolerated — and it is why there are several of them to choose between.

That context matters because it frames the biologic decision. By the time biologics are on the table, the question is rarely 'should we treat aggressively?' but 'which of several strong, effective options fits this particular person best?' With biologics, the choice is about fit, not about which drug is strongest.

How severity is measured

Before choosing a biologic, a clinician needs a shared sense of how bad the psoriasis is, because 'moderate-to-severe' is the threshold that opens the door to systemic treatment. Severity is judged by more than a single number: how much body-surface area is covered, where the plaques sit, and how much they affect daily life all count. People often ask how is psoriasis severity measured, and the honest answer is a mix of objective extent and real-world impact.

Body-surface-area estimates and formal scores put a figure on it, but a small amount of psoriasis in a high-impact spot — the hands, the genitals, the face — can count as severe because of what it does to function and quality of life. Judging psoriasis severity is the groundwork for every choice that follows, because the same disease at different severities gets very different treatment.

Getting the severity right is not bureaucratic box-ticking. It sets the whole direction: mild disease is usually handled with creams, moderate-to-severe disease is what justifies the reach of a systemic drug, and a heavy impact on daily life can move a case up a category on its own.

The biologic classes at a glance

Psoriasis biologics are grouped by the immune signal they block, and the main families are TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and the older IL-12/23 inhibitor. All are recommended options for moderate-to-severe plaque psoriasis, each with its own profile of how well and how fast it works, how often it is injected, and what needs monitoring 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The main biologic classes for moderate-to-severe psoriasis (TNF, IL-17, IL-23, and IL-12/23 inhibitors), and that dosing schedules and safety monitoring — including screening for infections such as latent tuberculosis and hepatitis before starting — are part of choosing and using a biologic.. This is the menu a dermatologist chooses from.

Broadly, the newer IL-23 and IL-17 agents tend to be highly effective for skin, while tnf inhibitors for psoriasis such as adalimumab have the longest track record and treat several related conditions. None is 'the best' for everyone, which is exactly why the rest of this article is about the factors that separate them. If you want the head-to-head view, that is the work of a proper psoriasis biologics compared breakdown; here the focus is on what makes one fit you.

A few practical differences distinguish the families. Some require more frequent injections, especially at first; others settle into an every-few-months rhythm once started. The older TNF inhibitors have the deepest safety track record and treat several conditions beyond skin, while the IL-23 and IL-17 classes were designed more specifically for psoriasis. All of them share a basic requirement: before starting, a clinician checks for infections and other risks, and monitoring continues while a person is on treatment 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The main biologic classes for moderate-to-severe psoriasis (TNF, IL-17, IL-23, and IL-12/23 inhibitors), and that dosing schedules and safety monitoring — including screening for infections such as latent tuberculosis and hepatitis before starting — are part of choosing and using a biologic..

Psoriatic arthritis is the biggest steer

The single factor that most often decides the class is whether psoriasis comes with joint disease. Psoriatic arthritis — pain, stiffness, and swelling in joints or where tendons attach — is common in people with psoriasis, and when it is present, the goal becomes treating skin and joints with one medicine. Guidelines conditionally favor starting a TNF-inhibitor biologic over older oral drugs for active psoriatic arthritis, and IL-17 and IL-12/23 agents are also used 3Ref 3Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.That in active psoriatic arthritis, guidelines conditionally favor starting a TNF-inhibitor biologic over older oral small-molecule drugs, and that IL-17 and IL-12/23 agents are also used — the basis for joint disease steering biologic class choice..

This is why a dermatologist will ask about aching joints, morning stiffness, and swollen fingers or toes even at a skin visit. A biologic that helps the skin but leaves the joints untreated is a missed opportunity, and some agents that are excellent for skin are less established for joints. Catching the arthritis changes the shortlist before the skin does.

Even short of formal arthritis, subtle joint symptoms or a strong family history can nudge a clinician toward a class with joint evidence, on the logic that it is easier to cover both from the start than to switch later. It is one of the clearest examples of the guiding principle: the biologic is chosen for the whole person, not the skin in isolation 3Ref 3Singh JA, Guyatt G, Ogdie A, et al. (2019).2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.That in active psoriatic arthritis, guidelines conditionally favor starting a TNF-inhibitor biologic over older oral small-molecule drugs, and that IL-17 and IL-12/23 agents are also used — the basis for joint disease steering biologic class choice..

The other conditions that tip the choice

Beyond arthritis, a person's other health conditions can move a biologic up or down the list, which is why guidelines urge screening for the conditions that travel with psoriasis — including cardiovascular disease, metabolic syndrome, mood disorders, and inflammatory bowel disease 4Ref 4American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.That psoriasis care includes screening for and awareness of comorbidities — psoriatic arthritis, cardiovascular disease, metabolic syndrome, and psychiatric conditions — which inform treatment decisions.. Psoriasis itself is linked to a higher risk of cardiovascular disease, driven by the same body-wide inflammation that inflames the skin, and the association is stronger in more severe disease 5Ref 5Garshick MS, Ward NL, Krueger JG, Berger JS (2021).Cardiovascular Risk in Patients With Psoriasis: JACC Review Topic of the Week.That psoriasis is associated with an increased risk of cardiovascular disease driven by systemic inflammation, with higher risk in more severe disease..

Several conditions steer the pick directly. Inflammatory bowel disease tends to favor agents that also treat the gut and to make one class less suitable. A history of certain infections — including tuberculosis and hepatitis — or a demyelinating condition affects which drug is safe, and clinicians screen for infections such as latent tuberculosis and hepatitis before starting a biologic and monitor during treatment 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The main biologic classes for moderate-to-severe psoriasis (TNF, IL-17, IL-23, and IL-12/23 inhibitors), and that dosing schedules and safety monitoring — including screening for infections such as latent tuberculosis and hepatitis before starting — are part of choosing and using a biologic.. Family planning and pregnancy matter too.

In practice, that pre-treatment work-up commonly includes screening for latent tuberculosis and for hepatitis, a review of vaccinations, and a baseline of bloodwork, with periodic checks afterward 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The main biologic classes for moderate-to-severe psoriasis (TNF, IL-17, IL-23, and IL-12/23 inhibitors), and that dosing schedules and safety monitoring — including screening for infections such as latent tuberculosis and hepatitis before starting — are part of choosing and using a biologic.. The point is not to make biologics sound dangerous — for many people they are well tolerated — but to catch the specific, screenable risks before they matter, which is part of what turns a powerful medicine into a safe one for a given person. The condition that most changes a biologic choice is often not the psoriasis — it is what else the person is living with.

The practical factors: dosing, past treatments, access

Once the medical shortlist is set, practical details often decide between similar options. How the drug is given and how often — some are injected every week or two, others every few months after an initial loading period — matters for someone who dreads needles or travels constantly, and dosing schedules are part of what guidelines lay out for each agent 2Ref 2American Academy of Dermatology; National Psoriasis Foundation (2019).Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.The main biologic classes for moderate-to-severe psoriasis (TNF, IL-17, IL-23, and IL-12/23 inhibitors), and that dosing schedules and safety monitoring — including screening for infections such as latent tuberculosis and hepatitis before starting — are part of choosing and using a biologic.. Preference here is legitimate, not trivial: the best biologic is the one a person will actually keep taking.

What you have already tried also shapes the next move. If one class did not work or stopped working, the next choice is usually a different class rather than another drug in the same family. And insurance coverage is a real constraint — plans often require trying certain drugs first, and that step therapy can determine the starting point regardless of a doctor's first preference.

Speed can matter too. Someone with severe, distressing disease and an upcoming milestone may weigh how quickly a biologic tends to work, while someone stable may care more about the convenience of infrequent dosing. And because coverage and cost vary so much, it is reasonable to ask not only which biologic is best on the merits but which ones a given plan will actually approve without a long fight. None of these is a medical reason in the strict sense, but all of them shape which biologic a real person ends up on.

How to weigh the numbers you'll hear

When a dermatologist compares biologics, numbers get quoted — response rates, side-effect risks — and how those numbers are framed changes how alarming or reassuring they sound. Research on risk communication finds that absolute risks and natural frequencies, like '2 out of 100 people,' are understood far better than relative-risk statements or vague percentages, and that relative risk in particular tends to exaggerate a difference 6Ref 6Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S (2007).Helping Doctors and Patients Make Sense of Health Statistics.That risk is understood better when communicated as absolute risks and natural frequencies than as relative risks or vague percentages, and that relative-risk framing tends to exaggerate differences — the basis for asking for benefit and side-effect numbers in a usable form..

The practical move is to ask for the numbers in a form you can actually use: out of 100 people like me on this drug, how many get this benefit, and how many get this side effect? Framed that way, a comparison between two biologics becomes something you can weigh rather than something that just sounds frightening or impressive. It is also fair to ask how confident the numbers are — whether they come from head-to-head trials or from comparing separate studies — since a difference that looks decisive on a chart can shrink once the uncertainty is shown 6Ref 6Gigerenzer G, Gaissmaier W, Kurz-Milcke E, Schwartz LM, Woloshin S (2007).Helping Doctors and Patients Make Sense of Health Statistics.That risk is understood better when communicated as absolute risks and natural frequencies than as relative risks or vague percentages, and that relative-risk framing tends to exaggerate differences — the basis for asking for benefit and side-effect numbers in a usable form.. Good decisions here are shared decisions, built on numbers presented honestly.

Putting it together

There is no universal best psoriasis biologic, which is the reassuring part: it means a less-than-perfect first choice is not a catastrophe, because there are several effective classes and switching is routine. The decision is a structured weighing — severity first, then psoriatic arthritis, then other conditions, then the practical realities of dosing, history, and coverage — arriving at the option that fits this person now.

That also means the most useful thing to bring to the conversation is a full picture of yourself: your joints, your other diagnoses, what you have tried, and what you can live with day to day. The biologic that gets chosen is the one that best answers all of those at once, and it is a decision made with a dermatologist rather than handed down. If the first biologic is not the right fit, changing to another class is a normal, expected part of the process.